Institutional members access full text with Ovid®

Share this article on:

Dietary transfatty acids and cancer risk

Hu, Jinfua; Vecchia, Carlo Lab,c; de Groh, Margareta; Negri, Evab; Morrison, Howarda; Mery, LesaThe Canadian Cancer Registries Epidemiology Research Group

European Journal of Cancer Prevention: November 2011 - Volume 20 - Issue 6 - p 530–538
doi: 10.1097/CEJ.0b013e328348fbfb
Research Papers: Life Style and Environment

This study assesses the association between dietary transfatty acid (TFA) intake and the risk of selected cancers. Mailed questionnaires were completed between 1994 and 1997 in eight Canadian provinces by 1182 incident, histologically confirmed cases of the stomach, 1727 of the colon, 1447 of the rectum, 628 of the pancreas, 3341 of the lung, 2362 of the breast, 442 of the ovary, 1799 of the prostate, 686 of the testis, 1345 of the kidney, 1029 of the bladder, 1009 of the brain, 1666 non-Hodgkin’s lymphomas, 1069 leukemias, and 5039 population controls. Information on dietary habits and nutrition intake was obtained using a food frequency questionnaire, which provided data on eating habits 2 years before the study. Odds ratios (OR) and 95% confidenc530e intervals (CI) were derived by unconditional logistic regression to adjust for total energy intake and other potential confounding factors. Dietary TFA were positively associated with the risk of cancers of the colon (OR: 1.38 for the highest vs. the lowest quartile), breast in premenopause (OR: 1.60), and prostate (OR: 1.42). There were a borderline association for pancreas cancer (OR: 1.38; P=0.06). No significant association was observed for cancers of the stomach, rectum, lung, ovary, testis, kidney, bladder, brain, non-Hodgkin’s lymphomas, and leukemia, although the ORs for the highest quartile were above unity for all neoplasms considered, except testis. Our findings add evidence that high TFA is associated with an increased risk of various cancers. Thus, a diet low in transfat may play a role in the prevention of several cancers.

aCentre for Chronic Disease Prevention and Control, Public Health Agency of Canada, Ottawa, Ontario, Canada

bIstituto di Ricerche Farmacologiche ‘Mario Negri’

cDepartment of Occupational Health, Università degli Studi di Milano, Milan, Italy

Correspondence to Dr Jinfu Hu, MD, Science Integration Division, Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada, 785 Carling Avenue, AL: 6807B, Ottawa, Ontario K1A 0K9, Canada Tel: +613 957 1070; fax: +613 941 2633; e-mail: Jinfu.hu@phac-aspc.gc.ca

Received March 18, 2011

Accepted May 5, 2011

© 2011 Lippincott Williams & Wilkins, Inc.